Every 8-K that Lunai Bioworks Inc. (RENB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RENB filings page.
Lunai Bioworks, Inc. reported that stockholders approved key proposals at a special meeting held on May 8, 2026. The main item was an amendment to the Certificate of Incorporation authorizing a reverse stock split of common stock at a ratio between 1-for-3 and 1-for-30, with the exact ratio to be set later by the board in its sole discretion.
Proposal 1, covering the reverse split, passed with 13,571,288 votes for, 1,153,415 against, and 61,177 abstentions. Proposal 2, allowing adjournment of the meeting if needed to gather more proxies for Proposal 1, was also approved with 13,626,029 votes for, 1,091,528 against, and 68,323 abstentions. The company notes that the reverse stock split and related actions are intended to address Nasdaq continued listing requirements, including the Bid Price Rule, and refers to risks if these efforts are not successful.
Lunai Bioworks, Inc. reports that Nasdaq staff has issued an additional determination letter stating its failure to meet the $35,000,000 market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2) after the grace period expired on April 27, 2026, which may serve as another basis for delisting.
The company previously received a Panel exception through May 1, 2026 to show compliance with the $2.5 million stockholders’ equity alternative and through June 1, 2026 for the bid price rule. To support equity compliance, Lunai completed a merger on May 1, 2026 and issued $20,000,000 in stated value of Series B Preferred Stock.
On May 8, 2026, stockholders approved a reverse stock split authorization in a range of 1-for-3 to 1-for-30, and the company plans to implement a ratio that brings its share price into compliance with the bid price requirement. The company has requested a short extension from the Nasdaq Panel and warns that failure to regain compliance could lead to delisting and a move to over-the-counter trading, with potential negative effects on liquidity and capital-raising ability.
Lunai Bioworks, Inc. completed a triangular merger to acquire Neurobridge IP Holdings, whose only assets are a multi‑jurisdictional patent portfolio for Alzheimer’s disease and neurological disorders. In exchange, Lunai issued eight shares of new Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000 and no cash.
The Series B Preferred Stock carries a senior $20,000,000 liquidation preference and is convertible, after separate stockholder approval, into up to 13,333,333 common shares at $1.50 per share, subject to beneficial ownership limits. Lunai aims to use this transaction and the preferred equity to satisfy Nasdaq’s $2.5 million stockholders’ equity requirement while it separately pursues a reverse stock split to address minimum bid price compliance.
Lunai Bioworks, Inc. is postponing its virtual Special Meeting of Stockholders from May 4, 2026 to May 8, 2026 at 9:00 a.m. Eastern Time. The meeting will still be held online and will consider proposals described in the company’s definitive proxy statement, including a Reverse Stock Split Proposal and an Adjournment Proposal.
The delay follows advice that timing rules for broker discretionary voting under New York Stock Exchange Rule 452 would likely not be met by the original date. Moving the meeting is intended to give stockholders more time to vote, help obtain a quorum, and allow brokers to vote uninstructed shares on routine matters. The record date remains April 10, 2026, and previously submitted proxies will be used unless changed or revoked.
Lunai Bioworks, Inc. entered debt exchange agreements with three noteholders, who agreed to cancel an aggregate $828,770.14 of secured promissory note principal and interest in return for 3,909,293 common shares at an implied price of $0.21 and warrants for 1,433,621 additional shares at a $0.21 exercise price, expiring on March 24, 2036.
The company also signed a binding $20.0 million Acquisition Agreement with Clemann Group SAS for blood-brain barrier delivery technology and CNS Alzheimer’s drug assets, structured as Series B Convertible Preferred Stock with a fixed $1.50 conversion price and a 19.9% beneficial ownership limitation, with no variable pricing or resets.
Lunai Bioworks, Inc. reports that Nasdaq has moved to delist its common stock, but the company has secured a hearing to contest this decision. Lunai requested a review after receiving an initial delisting notice, and Nasdaq’s Hearings Panel has now scheduled a hearing for March 26, 2026.
Because the hearing was granted, the planned delisting is temporarily on hold until the Panel issues a final written decision. The company cautions that there is no assurance the Panel will approve continued listing or that Lunai will meet Nasdaq’s ongoing listing standards going forward.
Lunai Bioworks, Inc. reported that Nasdaq staff has determined to delist its common stock from The Nasdaq Capital Market after the shares traded below the $1.00 minimum bid price for 30 consecutive business days from December 23, 2025 through February 5, 2026.
The company is not eligible for the usual 180-day cure period because it completed a 1-for-10 reverse stock split on September 30, 2025 under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Lunai has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays suspension and the planned Form 25 delisting filing, but there is no assurance the appeal will succeed.
Lunai Bioworks Inc. reported that it has re‑established compliance with Nasdaq Listing Rule 5620(a) after holding its annual meeting of shareholders on October 31, 2025.
Nasdaq had notified the company on July 7, 2025 that it was not in compliance for not holding an annual meeting within one year of its fiscal year end. Following the October 31 meeting, Nasdaq determined the company now complies with the rule and closed the matter.
Lunai Bioworks, Inc. reported the results of its annual meeting, with stockholders approving all four proposals. Shareholders elected eight directors to serve until the 2026 annual meeting, with the election conducted in accordance with Nasdaq Listing Rule 5605(e). The company recorded 1,314,903 broker non-votes in the director elections.
On executive pay, the say‑on‑pay advisory proposal passed with 5,548,091 votes for, 2,182,131 against, and 11,760 abstentions, with 1,314,903 broker non‑votes. Stockholders also approved the appointment of Sadler as the independent registered public accounting firm with 8,836,759 for, 18,002 against, and 202,124 abstentions. Amendments to the 2023 Equity Incentive Plan were approved with 6,956,477 for, 574,336 against, 211,169 abstentions, and 1,314,903 broker non‑votes.
Lunai Bioworks reported a Nasdaq compliance notice tied to market value. On October 27, 2025, the company received notice that it no longer meets the Nasdaq Capital Market’s $35 million minimum Market Value of Listed Securities requirement after being below that level for 30 consecutive business days. Lunai has 180 calendar days, until April 27, 2026, to regain compliance by maintaining an MVLS of $35 million or more for at least 10 consecutive business days.
The notice has no immediate effect on the listing, and the common stock will continue trading on Nasdaq under the symbol LNAI. If compliance is not regained by the deadline, Nasdaq may move to delist, and the company could appeal to a Nasdaq Hearings Panel, which would stay any delisting pending a decision. Lunai Bioworks said it will monitor MVLS and may consider corporate actions during the compliance period.
Lunai Bioworks regained Nasdaq compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq determined the company met the standard after the closing bid price was at least $1.00 for eleven consecutive business days from September 30, 2025 to October 14, 2025.
The company had previously received notice on April 14, 2025 that it was below the minimum bid price requirement. Lunai announced the compliance update in a press release dated October 16, 2025, filed as Exhibit 99.1.
Lunai Bioworks, Inc. announced a 1-for-10 reverse stock split of its common stock effective at 12:01 a.m. New York time on September 29, 2025. As approved by stockholders on August 15, 2025, the Board elected the maximum 1-for-10 ratio, combining every ten issued and outstanding shares into one share while leaving par value and the number of authorized common shares unchanged at 350,000,000.
Following the split, the company states outstanding shares will be reduced from 231,780,434 to approximately 23,178,096 after rounding up fractional shares. The reverse-split-adjusted common stock will begin trading on The Nasdaq Capital Market on September 30, 2025 under the trading symbol "LNAI" and a new CUSIP of 29350E203. The Certificate of Amendment and a press release are filed as exhibits to the Current Report.
Lunai Bioworks, Inc. reported that the Court of Amsterdam declared its indirect subsidiary Gedi Cube B.V. bankrupt on September 2, 2025, following Gedi’s voluntary petition after it could no longer meet its payment obligations. A court-appointed receiver will oversee the bankruptcy process. Lunai is evaluating how this development may affect its supply chain, customer relationships, and projects that had relied on Gedi, and management is putting contingency plans in place to limit operational disruption.
In connection with this bankruptcy, Lunai’s management concluded that a material impairment of assets has occurred and expects to record an impairment charge in the quarter ending September 30, 2025. The company plans to disclose the impairment in its upcoming Form 10-Q or earlier if available. Lunai emphasized that neither the parent company nor any other subsidiaries are seeking bankruptcy protection and that their operations will continue as usual.
Renovaro Inc. reported that it has amended its Restated Certificate of Incorporation to change its corporate name to Lunai Bioworks Inc. The amendment was filed in Delaware on August 18, 2025, and the name change became effective on August 20, 2025.
The company’s common stock will continue to trade on Nasdaq under the ticker symbol RENB, although the CUSIP number for the common stock will change as a result of the new name. The company also includes forward-looking statements about plans to hold its annual meeting and regain compliance with Nasdaq listing standards.
Renovaro Inc. (Nasdaq: RENB) disclosed in an 8-K that it received a Nasdaq Listing Rule 5620(a) deficiency notice on 7 July 2025 for failing to hold its FY 2024 annual shareholder meeting within 12 months of the 30 June 2024 fiscal year-end.
The company has 45 calendar days to submit a remediation plan; if Nasdaq accepts it, Renovaro could receive an extension until 29 December 2025 to regain compliance. Until then, the stock will continue trading on Nasdaq. Failure to file an acceptable plan or to hold the meeting by the deadline could lead to delisting.
Management states it is “working diligently” to prepare the plan and schedule the meeting “as soon as practicable.” No other operational or financial metrics were disclosed.